Article Details

Rilzabrutinib Shines in Phase 3 Trial of Tough-to-Treat Immune Thrombocytopenia

Retrieved on: 2024-12-08 15:37:37

Tags for this article:

Click the tags to see associated articles and topics

Rilzabrutinib Shines in Phase 3 Trial of Tough-to-Treat Immune Thrombocytopenia. View article details on hiswai:

Excerpt

For those with the condition, the body's immune system attacks platelets, causing platelet counts to drop below 100,000/μL of blood. The disease ...

Article found on: www.medscape.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up